About Syndax Pharmaceuticals, Inc. (adapted from Syndax Pharmaceuticals, Inc. prospectus):
They are a late-stage biopharmaceutical company focused on the development and commercialization of our lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers.

This description is adapted from Syndax SNDX prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.